GEN Exclusives

More »

The Lists

More »
Jul 8, 2013

Top 15 Vaccines of 2012

These top-sellers could be the booster shots the industry needs.

Top 15 Vaccines of 2012

Relatively few drug/vaccine developers are responsible for the top sellers on this list. [© Robert Hoetink -]

  • You’ve seen GEN’s list of biosimilars to watch; now, following is a list of 15 vaccines, ranked by sales and representing the 15 top-selling vaccines of 2012. Sales figures come mostly from data disclosed by vaccine developers, except where otherwise noted. Vaccines are listed by their name, their proper name as filed with FDA or furnished by vaccine developers, sales figures for 2012 and 2011, the percentage of year-over-year sales growth, the name of the vaccine developer/sponsor, and indications. The source for indications is FDA’s list of Vaccines Licensed for Immunization and Distribution in the U.S. with Supporting Documents, available online on the agency’s website.

    The list reveals, first off, how relatively few drug/vaccine developers are responsible for the top sellers. Merck & Co. and Sanofi account for more than half of the vaccines on the list, both individually and collectively; the two companies maintain a joint venture, Sanofi Pasteur MSD, which discloses sales results for only two of its vaccines. Other solid performers in vaccines include GlaxoSmithKline, which placed five vaccines on the list, and Pfizer, whose vaccine Prevnar 13 topped the list with nearly $4 billion in sales last year.

    Another pharma giant, Novartis, can be expected to show up on next year’s list given talk earlier this year that it planned in 2013 to launch the meningitis vaccine Bexsero, a Meningococcal Group B Vaccine [rDNA, component, adsorbed] for use against meningococcal serogroup B (MenB); and Flucelvax, the first cell-culture derived influenza vaccine approved in the U.S., designed to protect adults 18 years and older against seasonal flu. The latter is expected to be launched in time for the 2013–2014 flu season. Manufacturing ramp-ups to both launches account for Novartis’ vaccines and diagnostics division finishing last year with a $250 million loss on $1.9 billion in sales.

  • #15. Prevnar/Prevenar (7-valent)

    Pneumococcal 7-valent conjugate vaccine [Diphtheria CRM197 protein]

    2012 sales: $399 million

    2011 sales: $488 million

    % year-to-year sales growth: -18.2%

    Developer/Sponsor: Pfizer

    Indications: Immunization of infants two, four, six, and 12–15 months of age to prevent invasive pneumococcal disease; immunization of infants and toddlers against otitis media caused by vaccine serotypes

  • #14. Adacel

    Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

    2012 sales: €360 million ($469 million)1,2,3

    2011 sales: €314 million ($409 million)1,2

    % year-to-year sales growth: 14.6%

    Developer/Sponsor: Sanofi and Sanofi Pasteur MSD

    Indications: Diptheria, pertussis/whooping cough, tetanus

  • #13. Rotarix

    Rotavirus vaccine, live, oral

    2012 sales: £360 million ($549 million)1

    2011 sales: £300 million ($458 million)1

    % year-to-year sales growth: 20.0%

    Developer/Sponsor: GlaxoSmithKline

    Indications: Prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9), for use in infants six weeks to 24 weeks of age

  • #12. Pneumovax®23

    Pneumococcal vaccine, polyvalent

    2012 sales: $580 million4

    2011 sales: $427 million4

    % year-to-year sales growth: 16.5%

    Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD

    Indications: Vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine

  • #11. Synflorix®

    Pneumococcal polysaccharide conjugate vaccine (Nontypeable Haemophilus influenzae [NTHi] protein D, diphtheria or tetanus toxoid conjugates) adsorbed

    2012 sales: £385 million ($587 million)1

    2011 sales: £350 million ($534 million)1

    % year-to-year sales growth: 10.0%

    Developer/Sponsor: GlaxoSmithKline

    Indications: Active immunization of infants and children from six weeks up to five years of age against disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F (including sepsis, meningitis, pneumonia, bacteremia, and acute otitis media) and against acute otitis media caused by nontypeable Haemophilus influenzae.

  • #10. RotaTeq®

    Rotavirus vaccine, live oral, pentavalent

    2012 sales: $648 million5

    2011 sales: $695 million6

    % year-to-year sales growth: -6.8%

    Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD

    Indications: Prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a three-dose series to infants between the ages of six to 32 weeks

  • #9. Zostavax

    Zoster vaccine live

    2012 sales: $651 million4

    2011 sales: $332 million4

    % year-to-year sales growth: 96.1%

    Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD

    Indications: Prevention of herpes zoster (shingles) in individuals 50 years of age and older

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »